• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ERBB3 Gene Record

  • Summary
  • Interactions
  • Claims
  • ERBB3 2065 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    2065
    ERB-B2 RECEPTOR TYROSINE KINASE 3
    ERBB3
    ErbB-3
    HER3
    LCCS2
    MDA-BF-1
    c-erbB-3
    c-erbB3
    erbB3-S
    p180-ErbB3
    p45-sErbB3
    p85-sErbB3
    190151
    3431
    ENSG00000065361
    OTTHUMG00000170140
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860]
    1733
    P21860
    Receptor tyrosine-protein kinase erbB-3
    Proto-oncogene-like protein c-ErbB-3
    Tyrosine kinase-type cell surface receptor HER3
    ERBB3_HUMAN
    EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3)
    HER3 (ERBB3)
    PA27846
    Erbb3 tyrosine kinase receptor
    T86350
    FERLK
    VSCN1

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Type Domain
    Uniprot Status Swiss-Prot
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Human Readable Name KINASE
    Interpro Acc IPR001245
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (20 More Sources)

    Gene Categories: Category Details

    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
    Bidard FC et al., 2015, Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer., Ann Oncol
    Leary et al., 2015, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)., Clin. Cancer Res.
    Thomas et al., 2014, HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models., Oncotarget
    Capparelli et al., 2015, ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas., Cancer Res.
    Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
    Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.
    Sun et al., 2014, Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3., Cell Rep
    Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
    Cushman et al., 2015, Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)., Clin. Cancer Res.
  • MM-121   ERBB3

    Interaction Score: 8.24

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions TTD

  • AMG-888   ERBB3

    Interaction Score: 4.12

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • AV-203   ERBB3

    Interaction Score: 4.12

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC TTD

  • MM-111   ERBB3

    Interaction Score: 2.06

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Trial Name MM-111
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial

  • SAPITINIB   ERBB3

    Interaction Score: 2.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome ChemblInteractions

  • DULIGOTUZUMAB   ERBB3

    Interaction Score: 2.06

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome TTD

  • PATRITUMAB   ERBB3

    Interaction Score: 2.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • PERTUZUMAB   ERBB3

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status preclinical

    PMIDs:
    23680147 25216528 26206558


    Sources:
    DoCM CIViC

  • MARGETUXIMAB   ERBB3

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • DIMETHYLCURCUMIN   ERBB3

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • ELGEMTUMAB   ERBB3

    Interaction Score: 1.03

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METHYLCURCUMIN   ERBB3

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • POZIOTINIB   ERBB3

    Interaction Score: 0.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions MyCancerGenomeClinicalTrial

  • DACOMITINIB   ERBB3

    Interaction Score: 0.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions MyCancerGenomeClinicalTrial

  • SERIBANTUMAB   ERBB3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ISTIRATUMAB   ERBB3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • AFATINIB   ERBB3

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27044931 24685132


    Sources:
    CIViC

  • TRASTUZUMAB   ERBB3

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status preclinical

    PMIDs:
    23680147 30071039 25953157


    Sources:
    DoCM CIViC PharmGKB

  • AC-480   ERBB3

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name AC480
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • OSIMERTINIB MESYLATE   ERBB3

    Interaction Score: 0.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAPATINIB   ERBB3

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status preclinical
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    23680147 25398453 25953157


    Sources:
    DoCM CIViC PharmGKB

  • SELUMETINIB   ERBB3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24685132 25952648


    Sources:
    CIViC

  • GEFITINIB   ERBB3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    24685132


    Sources:
    CIViC MyCancerGenomeClinicalTrial PharmGKB

  • TRAMETINIB   ERBB3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25952648


    Sources:
    CIViC

  • CETUXIMAB   ERBB3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25520391


    Sources:
    CIViC

  • CURCUMIN   ERBB3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25753330


    Sources:
    DTC

  • DOCETAXEL   ERBB3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • CARBOPLATIN   ERBB3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • ERLOTINIB   ERBB3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VANDETANIB   ERBB3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Epidermal growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • Ensembl: ENSG00000065361

    • Version: 101_38

    Alternate Names:
    ERBB3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: P21860

    • Version: 11-September-2012

    Alternate Names:
    P21860 Uniprot Accession
    ERBB3 Uniprot Gene Name
    ENSG00000065361 Ensembl Gene Id

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000065361

    • Version: 26-July-2011

    Alternate Names:
    RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860] Description
    ERBB3 Display Id
    ENSG00000065361 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P21860

    • Version: January-2014

    Alternate Names:
    ERBB3 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • PharmGKB: ERBB3

    • Version: 18-August-2020

    Alternate Names:
    PA27846 PharmGKB ID

    Gene Info:

    Publications:
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One

  • CIViC: ERBB3

    • Version: 14-September-2020

    Alternate Names:
    2065 Entrez Gene ID
    1733 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Sun et al., 2014, Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3., Cell Rep
    Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
    Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.

  • TTD: Erbb3 tyrosine kinase receptor

    • Version: 2020.06.01

    Alternate Names:
    Erbb-3 TTD Gene Abbreviation
    T86350 TTD Target ID

    Gene Info:

    Publications:
    Dey N et al., 2015, A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK., Am J Transl Res

  • DoCM: ERBB3

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell

  • DTC: ERBB3

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem

  • ChemblInteractions: HER3

    • Version: chembl_23

    Alternate Names:
    HER3 GENE_SYMBOL
    ERBB3 GENE_SYMBOL
    Receptor tyrosine-protein kinase erbB-3 UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000065361

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000065361 Gene Symbol
    ERBB3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: ERBB3

    • Version: 20-Jun-2017

    Alternate Names:
    2065 Entrez Gene Id
    ERBB3 MyCancerGenome Gene Symbol
    HER3 (ERBB3) MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • TALC: HER3

    • Version: 12-May-2016

    Alternate Names:
    HER3 Gene Symbol

    Gene Info:

    Publications:

  • HumanProteinAtlas: ERBB3

    • Version: 19.3

    Alternate Names:
    ENSG00000065361 Ensembl Gene ID
    HER3 Human Protein Atlas Gene Synonym
    LCCS2 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • GO: ERBB3

    • Version: 01-February-2022

    Alternate Names:
    HER3 GO Gene Synonym

    Gene Info:

    Gene Categories:
    TYROSINE KINASE

    Publications:

  • Tempus: ERBB3

    • Version: 11-November-2018

    Alternate Names:
    ERBB3 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: ERBB3

    • Version: 27-Jun-2013

    Alternate Names:
    2065 Gene ID
    ErbB-3 dGene Synonym
    HER3 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • Pharos: ERBB3

    • Version: 01-February-2022

    Alternate Names:
    Receptor tyrosine-protein kinase erbB-3 Gene Name
    P21860 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • MyCancerGenomeClinicalTrial: ERBB3

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: ERBB3

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: ERBB3

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: ERBB3

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: ERBB3

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: ERBB3

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21